Eli Lilly and Company (LLY) is a leading global pharmaceutical firm focused on treatments for diabetes, obesity, oncology, and other serious conditions. On June 26, 2026, LLY stock rose sharply, advancing roughly 6.70% from the prior session’s closing price of $1,127.69. The advance reflected immediate market reaction to positive regulatory developments in Europe concerning one of its oncology assets.
A key European Medicines Agency committee issued a positive opinion recommending marketing authorization for Jaypirca in a broader CLL patient population. If finalized by the European Commission, the approval would allow use across all lines of therapy, significantly expanding the drug’s addressable market in the region. Investors viewed the development as validation of Lilly’s oncology strategy and a potential near-term revenue driver.
Volume was notably higher than average as the news circulated, underscoring broad participation in the move. The advance aligned with strength in other healthcare names and occurred while major indices traded mixed to higher. Technically, the stock pushed well above recent session highs, breaking through resistance near the $1,150–$1,180 zone and approaching new intraday peaks.
Tickeron’s Trending AI Robots page highlights the platform’s strongest-performing AI trading bots under prevailing market conditions. Tickeron offers hundreds of AI-powered bots spanning thousands of tickers and a wide range of strategies, timeframes, and performance metrics. Only the top performers are featured in the curated trending section. The page serves as a dynamic resource for traders seeking data-driven automation tools. Visit the page to explore current trending bots and learn more about Tickeron’s offerings.
Investors will monitor the European Commission’s final decision on Jaypirca and any additional pipeline updates. Lilly’s upcoming earnings release and ongoing clinical trial readouts in obesity, diabetes, and oncology remain key focal points. Sector developments, including competitive dynamics in GLP-1 therapies and broader regulatory trends, will also influence sentiment. Risks include potential delays in approvals, competitive pressures, and macroeconomic factors affecting healthcare valuations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The RSI Oscillator for LLY moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 19 of the 23 cases the stock moved higher. This puts the odds of a move higher at 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 57 cases where LLY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.
LLY moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 262 of 375 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 225 of 303 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 53 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor